Mvasi Caution For Usage

Incompatibilities: This medicinal product must not be mixed with other medicinal products except those mentioned as follows.
A concentration dependent degradation profile of bevacizumab was observed when diluted with glucose solutions (5%).
Special precautions for disposal and other handling: MVASI should be prepared by a healthcare professional using aseptic technique to ensure the sterility of the prepared solution.
The necessary amount of bevacizumab should be withdrawn and diluted to the required administration volume with sodium chloride 9 mg/mL (0.9%) solution for injection. The concentration of the final bevacizumab solution should be kept within the range of 1.4 mg/mL to 16.5 mg/mL. In the majority of the occasions the necessary amount of MVASI can be diluted with 0.9% sodium chloride solution for injection to a total volume of 100 mL.
Parenteral medicinal products should be inspected visually for particulate matter and discolouration prior to administration.
No incompatibilities between MVASI and polyvinyl chloride or polyolefin bags or infusion sets have been observed.
MVASI is for single-use only, as the product contains no preservatives. Any unused medicinal product or waste material should be disposed in accordance with local requirements.